• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Investor Forum: Now Available for Online Viewing

    6/13/25 8:35:00 AM ET
    $ATNM
    $BPTH
    $COCH
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNM alert in real time by email

    NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing.

    REGISTER AND VIEW PRESENTATIONS

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

    investor materials from the company's resource section.

    Select companies are accepting 1x1 management meeting requests through June 17.

    June 11th





    Presentation
    Ticker(s)
    Nika Pharmaceuticals(OTCQB:NIKA)
    Tivic Health Systems Inc.(NASDAQ:TIVC)
    Adia Nutrition, Inc.(OTCQB:ADIA)
    Sandoz Group AG(OTCQX:SDZNY, SIX: SDZ))



    June 12
    th





    Presentation
    Ticker(s)
    CSL Ltd.(OTCQX:CSLLY, ASX: CSL))
    Sharps Technology, Inc.(NASDAQ:STSS)
    Heidelberg Pharma AG(XETRA: HPHA)
    SBC Medical Group Holdings Incorporated(NASDAQ:SBC)
    Actinium Pharmaceuticals, Inc.(NYSE:ATNM)
    IMUNON, Inc.(NASDAQ:IMNN)
    Bio-Path Holdings, Inc.(OTCQB:BPTH)
    Perimeter Medical Imaging AI, Inc.(OTCQX:PYNKF, TSXV:PINK)
    MetaVia Inc.(NASDAQ:MTVA)
    Conavi Medical Corp.(OTCQB:CNVIF, TSXV:CNVI)
    Vycor Medical, Inc.(OTCQB:VYCO)
    Envoy Medical, Inc.(NASDAQ:COCH)
    Starpharma Holdings Ltd.(OTCQX:SPHRY, ASX: SPL))



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact:

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $ATNM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNM
    $BPTH
    $COCH
    $IMNN

    CompanyDatePrice TargetRatingAnalyst
    SBC Medical Group Holdings Incorporated
    $SBC
    3/6/2026$8.00Buy
    BTIG Research
    MetaVia Inc.
    $MTVA
    9/4/2025$12.00Buy
    H.C. Wainwright
    MetaVia Inc.
    $MTVA
    12/30/2024$12.00Buy
    H.C. Wainwright
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/7/2024$16.00 → $2.00Buy → Neutral
    B. Riley Securities
    Envoy Medical Inc.
    $COCH
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    5/14/2024$25.00Overweight
    Stephens
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/6/2023$11.60Buy
    HSBC Securities
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    2/21/2023Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wolf Lisa G

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    3/19/26 9:14:41 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by SBC Medical Group Holdings Incorporated

    4 - SBC Medical Group Holdings Inc (0001930313) (Issuer)

    3/10/26 9:54:07 PM ET
    $SBC
    Medical/Nursing Services
    Health Care

    Chief Operating Officer Handley Michael K converted options into 8,824 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    2/20/26 4:19:42 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on SBC Medical Group with a new price target

    BTIG Research initiated coverage of SBC Medical Group with a rating of Buy and set a new price target of $8.00

    3/6/26 8:35:41 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    SEC Filings

    View All

    SEC Form 10-K filed by Actinium Pharmaceuticals Inc. (Delaware)

    10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

    3/30/26 5:39:32 PM ET
    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Tivic Health Systems Inc.

    10-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/30/26 5:34:51 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Envoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    3/27/26 4:01:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results

    Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical" or the "Company"), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year

    3/27/26 6:40:00 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

    48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned Phase 1 Part 3 16-Week Titration Study to Evaluate 48 mg (1-Step) and 64 mg (2-Step) Regimen Receives IRB Approval; Initiation Expected in April of 2026 with Data Anticipated in the Fourth Quarter $10.3 Million in Cash and Cash Equivalents at End of Year and Proceeds From January 2026 Public Offering is Expected to Fund the Company Into the Fourth Quarter of 2026CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announc

    3/26/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

    The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated with PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated median increase in OS of 24.2 months Enrollment in IMUNON's Phase 3 pivotal trial for IMNN-001 remains ahead of plan, supported by continued strong interest from investigators and medical community LAWRENCEVILLE, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced final cl

    3/25/26 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Leadership Updates

    Live Leadership Updates

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions

    3/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure

    SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical" or the "Company"), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the appointment of Sheng-FU Hsiao as Chief Technology Officer (CTO), effective March 1, 2026. This appointment aligns with the Company's 2026 management strategy, "Sophistication of Management Structure through AI and DX," and strengthens its leadership team to accelerate technological transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302064873/en/SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging

    3/2/26 7:00:00 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Financials

    Live finance-specific insights

    View All

    SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results

    Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical" or the "Company"), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year

    3/27/26 6:40:00 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

    LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1

    3/24/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SBC Medical to Announce Q4 and Full‑Year 2025 Financial Results

    IRVINE, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical" or the "Company"), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced it will release its financial results for the fourth quarter and fiscal year ended December 31, 2025, before U.S. market open on March 27, 2026.  Management will host an earnings conference call on March 27, 2026, at 8:30 a.m. Eastern Time to discuss the Company's financial performance, operational highlights, and key priorities for 2026. A question‑and‑answer session with analysts and investors will follow the prepared remark

    3/13/26 8:00:00 AM ET
    $SBC
    Medical/Nursing Services
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Imunon Inc.

    SC 13G/A - Imunon, Inc. (0000749647) (Subject)

    11/14/24 12:17:50 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/14/24 8:49:34 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care